Lördag 18 April | 10:32:15 Europe / Stockholm

Svenska | English

Argenx

Filter

År

Typ

Språk

Rensa

2026-04-18 07:00:00 argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

2026-03-20 21:01:00 argenx announces Annual General Meeting of Shareholders on May 6, 2026

2026-03-06 07:00:00 argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline 619,70 EUR | -2,19%

2026-02-26 07:00:00 argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update 658,70 EUR | -7,39%

2026-02-26 06:30:00 argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis 658,70 EUR | -7,39%

2026-02-23 07:00:00 argenx to Present at TD Cowen 46th Annual Healthcare Conference 702,10 EUR | -2,26%

2026-01-13 07:00:00 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG 691,10 EUR | +3,46%

2026-01-12 07:00:00 argenx Highlights 2026 Strategic Priorities 668,00 EUR | -3,58%

2026-01-06 07:00:00 argenx to Present at 44th Annual J.P. Morgan Healthcare Conference 687,10 EUR | +0,22%

2026-01-05 07:00:00 argenx Announces Leadership Transition Marking Next Evolution of Growth 685,60 EUR | -5,76%

2025-12-15 07:00:00 argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 716,00 EUR | -5,37%

2025-11-18 22:01:00 argenx Announces Results of Extraordinary General Meeting of Shareholders 788,60 EUR | -0,87%

2025-10-30 07:00:00 argenx Reports Third Quarter 2025 Financial Results and Provides Business Update 693,20 EUR | -3,27%

2025-10-29 16:00:00 argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients 716,60 EUR | +0,06%

2025-10-23 07:00:00 argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 706,10 EUR | -2,09%

2025-10-15 07:00:00 argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session 699,30 EUR | +1,64%

2025-10-03 22:01:00 argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

2025-08-28 07:00:00 argenx to Present at Upcoming Investor Conferences 600,60 EUR | -2,09%

2025-08-25 07:00:00 argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

2025-08-19 07:00:00 argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 564,20 EUR | -0,67%

2025-08-12 12:45:00 argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis 552,20 EUR | -2,01%

2025-07-31 07:00:00 argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update 598,70 EUR | +16,09%

2025-07-24 07:00:00 argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 492,65 EUR | +0,47%

2025-06-30 07:00:00 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes 471,65 EUR | -1,75%

2025-06-20 19:00:00 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy 475,25 EUR | +1,17%

2025-06-11 00:01:00 argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease 507,05 EUR | -1,24%

2025-06-03 07:00:00 argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 510,70 EUR | +1,47%

2025-05-28 22:01:00 argenx Announces Results of Annual General Meeting of Shareholders 512,05 EUR | -0,37%

2025-05-08 07:00:00 argenx Reports First Quarter 2025 Financial Results and Provides Business Update 484,65 EUR | -10,91%

2025-05-06 07:00:00 argenx to Present at BofA Securities 2025 Health Care Conference 568,40 EUR | -0,99%

2025-05-01 07:00:00 argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 559,70 EUR | 0,00%

2025-04-28 07:00:00 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 541,40 EUR | +1,46%

2025-04-11 22:01:00 argenx Announces Annual General Meeting of Shareholders on May 27, 2025 504,65 EUR | +1,07%

2025-04-10 23:47:43 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy 504,65 EUR | +1,07%

2025-04-08 07:00:00 argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP 517,55 EUR | +4,05%

2025-03-07 07:00:00 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting 555,50 EUR | -4,57%

2025-02-27 07:00:00 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update 615,70 EUR | +3,06%

2025-02-25 07:00:00 argenx to Present at TD Cowen 45th Annual Healthcare Conference 608,00 EUR | -0,69%

2025-02-20 07:00:00 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 608,60 EUR | -0,62%

2025-01-13 07:00:00 argenx Highlights 2025 Strategic Priorities 638,50 EUR | -1,30%

2025-01-06 07:00:00 argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference 607,30 EUR | +0,35%

2024-12-27 07:00:00 argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy 601,20 EUR | +0,74%

2024-11-26 07:00:00 argenx to Present at Upcoming Investor Conferences 584,00 EUR | +1,07%

2024-11-20 07:00:00 argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 565,20 EUR | +5,29%

2024-11-11 13:30:00 argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China 558,30 EUR | +1,62%

2024-11-05 07:00:00 argenx to Participate at Upcoming Investor Conferences 540,60 EUR | -0,28%

2024-10-31 07:00:00 argenx Reports Third Quarter 2024 Financial Results and Provides Business Update 539,70 EUR | +5,04%

2024-10-24 07:00:00 argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 511,70 EUR | -2,21%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Argenx

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden